



ASX

AUSTRALIAN SECURITIES EXCHANGE

MARKET RELEASE

17 February 2014

Prana Biotechnology Limited

TRADING HALT

The securities of Prana Biotechnology Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 19 February 2014 or when the announcement is released to the market.

Security Code: PBT

Dean Litis

Principal Adviser, Listings Compliance (Melbourne)

Mr Kobe Li
ASX Markets Supervision Pty Ltd
Advisor, Issues, Melbourne
Level 45 Rialto South Tower
525 Collins Street
Melbourne VIC 3000

17 February 2014

Dear Kobe,

Request for Trading Halt for Prana Biotechnology Limited

Pursuant to Listing Rule 17.1, Prana Biotechnology Limited (“the Company”) requests a trading halt be granted by the Australian Securities Exchange with respect to the Company’s ordinary shares (ASX:PBT).

In requesting the trading halt, the Company provides the following information:

- The trading halt is necessary as the Company is preparing an announcement for the market in relation to the results of its Reach2HD Phase 2 Huntington’s Disease Trial;
- The Company requests the trading halt remain in place until the earlier of; commencement of trade on Wednesday 19 February 2014, or the time that the Company makes an announcement about the results of the Phase 2 Huntington’s Disease Trial;
- The Company is not aware of any reason why the trading halt should not be granted; and
- The Company is not aware of any other information necessary to inform the market about the trading halt.

Yours Faithfully



Mr Richard Revelins
Company Secretary

For personal use only